# ZAYVORA Formulation Intelligence Engine™ (ZFIE)
## Scientific Engine Logic & Algorithms Master Blueprint
**Document Identifier:** `ZAY-ZFIE-ALGO-2026-V1`  
**Security Classification:** Highly Confidential / Core Proprietary Intellectual Property  
**System:** ZAYVORA Health OS™  
**Architectural Tier:** Scientific Layer 2 — Computational Engines & Algorithmic Specifications  
**Principle:** $Knowledge \to Inference \to Evidence \to Safety \to Validation \to Clinician \to Action \to Outcome$

---

## 1. Executive Architecture & Engine Inventory

This Master Blueprint formally specifies the exact algorithmic, mathematical, statistical, and computational mechanics powering the 10 core engines of the **ZAYVORA Formulation Intelligence Engine™ (ZFIE)**. 

No engine is permitted to operate as an ungrounded "black box". Every engine adheres to strict input contracts, deterministic mathematical equations, calibrated uncertainty intervals, explicit failure modes, and auditable evidence provenance.

```text
                               ZFIE COMPUTATIONAL PIPELINE
                                            │
  ┌─────────────────────────────────────────┼────────────────────────────────────────┐
  │                                         │                                        │
  ▼                                         ▼                                        ▼
[ENGINE 1]                             [ENGINE 2]                               [ENGINE 3]
Compound Mapping &                     In Silico Target                         Network Pharmacology &
Stereochemical Resolution               Affinity Prediction                      Pathway Perturbation
  │                                         │                                        │
  └─────────────────────────────────────────┼────────────────────────────────────────┘
                                            ▼
                                       [ENGINE 4]
                               Pharmacokinetics (PK/PBPK)
                                  & Exposure Prediction
                                            │
  ┌─────────────────────────────────────────┼────────────────────────────────────────┐
  │                                         │                                        │
  ▼                                         ▼                                        ▼
[ENGINE 5]                             [ENGINE 6]                               [ENGINE 7]
Contextual Safety &                    Contradiction & Conflict                 Multi-Component Synergy
Toxicology Gatekeeper                  Resolution Engine                        (Bliss/Loewe/ZIP)
  │                                         │                                        │
  └─────────────────────────────────────────┼────────────────────────────────────────┘
                                            ▼
                                       [ENGINE 8]
                               Unani ↔ Biomedical Semantic
                              Humoral-Molecular Translation
                                            │
  ┌─────────────────────────────────────────┼────────────────────────────────────────┐
  │                                         │                                        │
  ▼                                         ▼                                        ▼
[ENGINE 9]                             [ENGINE 10]                              [ENGINE 11]
Formulation Compiler &                 Next-Best Experiment                     Scientific Memory &
Multi-Objective Optimization           Recommendation Framework                 Continuous Knowledge Decay
```

---

## Engine 1: Compound Mapping & Stereochemical Resolution Engine

### 1.1 Objective & Scope
Resolves vernacular, classical Unani, Arabic, Persian, and Ayurvedic botanical terms into distinct phytochemical constituents with canonical stereochemical representations (SMILES, InChI, InChIKey), PubChem CIDs, and ChEMBL IDs.

### 1.2 Mathematical Formulation & Algorithm
1. **Multilingual Levenshtein-Jaro-Winkler Distance ($D_{JW}$):**
   $$\text{Sim}_{JW}(s_1, s_2) = \text{Jaro}(s_1, s_2) + \ell \cdot p \cdot (1 - \text{Jaro}(s_1, s_2))$$
   Where $\ell$ is length of common prefix (up to 4 chars), and $p = 0.1$ is the standard scaling factor.
2. **Canonical Tautomer & Resonance Normalization:**
   Uses InChIKey Layer 1 (connectivity) and Layer 2 (stereochemistry/isotopic substitution) to partition stereoisomers from planar compounds:
   $$\text{InChIKey} = \text{Hash}_{SHA256}(\text{Connectivity})[:14] + \text{Hash}_{SHA256}(\text{Stereo})[:10] + \text{Version}$$

### 1.3 Input & Output Contracts
- **Input Schema:**
  ```json
  {
    "query_name": "Suranjan Shirin",
    "botanical_hint": "Colchicum autumnale L.",
    "plant_part": "Corm",
    "language": "URDU"
  }
  ```
- **Output Schema:**
  ```json
  {
    "canonical_id": "ZAY-CMP-0001",
    "common_name": "Colchicine",
    "smiles": "CC(=O)NC1CCC2=CC(=O)C(=C(C2=C3C1=CC(=C(C3=O)OC)OC)OC)OC",
    "inchikey": "IAKHMKGGTNLKSZ-INIZCTEOSA-N",
    "pubchem_cid": 6167,
    "chembl_id": "CHEMBL84",
    "confidence_score": 0.994,
    "resolution_tier": "DETERMINISTIC_EXACT"
  }
  ```

### 1.4 Failure Modes & Boundaries
- **Failure Condition:** Ambiguous common name mapping to disparate chemical scaffolds (e.g., "Afyoon" vs synthetic opioids).
- **Remediation:** Flagged as `AMBIGUOUS_TAXONOMIC_COLLISION`; requires human pharmacognosist manual disambiguation.

---

## Engine 2: In Silico Target Affinity & Docking Prediction Engine

### 2.1 Objective & Scope
Predicts binding affinity between phytochemical constituents and human therapeutic protein targets.

### 2.2 Mathematical Formulation & Algorithm
1. **Binding Free Energy Scoring Function ($\Delta G_{\text{bind}}$):**
   $$\Delta G_{\text{bind}} = \Delta G_{\text{vdW}} + \Delta G_{\text{hbond}} + \Delta G_{\text{elec}} + \Delta G_{\text{desolv}} + \Delta G_{\text{tor}}$$
   Where:
   - $\Delta G_{\text{vdW}} = \sum_{i,j} \left( \frac{A_{ij}}{r_{ij}^{12}} - \frac{B_{ij}}{r_{ij}^6} \right)$
   - $\Delta G_{\text{hbond}} = \sum_{i,j} E(t) \left( \frac{C_{ij}}{r_{ij}^{12}} - \frac{D_{ij}}{r_{ij}^{10}} \right)$
   - $\Delta G_{\text{desolv}} = \sum_{i} S_i V_j e^{-r_{ij}^2 / 2\sigma^2}$
2. **Dissociation Constant ($K_d$) Conversion:**
   $$K_d = \exp\left( \frac{\Delta G_{\text{bind}}}{R \cdot T} \right)$$
   Where $R = 1.987 \times 10^{-3} \text{ kcal/mol}\cdot\text{K}$ and $T = 310.15 \text{ K}$ (physiological temperature).

### 2.3 Evidence Grading Rule
- **Mandatory Invariant:** All purely computational docking affinities are classified strictly as **Evidence Level E2 (Computational Hypothesis)**.
- **Promotion Block:** Never promoted to E3 (In Vitro) or E5 (Clinical) without physical binding assay confirmation ($K_d$ via SPR or ITC).

### 2.4 Failure Modes
- Metalloprotein active sites lacking accurate forcefield parameterization (e.g. Zinc finger domains).
- Flexible macromolecular loops undergoing induced-fit conformational changes exceeding $3.5\text{ \AA}$ RMSD.

---

## Engine 3: Network Pharmacology & Pathway Perturbation Engine

### 3.1 Objective & Scope
Constructs bipartite ligand-target-pathway graphs and computes pathway perturbation indices across physiological axes.

### 3.2 Mathematical Formulation
1. **Topological Centrality (Random Walk with Restart - RWR):**
   $$\mathbf{p}_{t+1} = (1 - r) \mathbf{W} \mathbf{p}_t + r \mathbf{p}_0$$
   Where $\mathbf{W}$ is the column-normalized adjacency matrix of the protein-protein interaction network (STRING v12), $r = 0.3$ is the restart probability, and $\mathbf{p}_0$ is the seed vector of compound targets.
2. **Pathway Perturbation Score ($S_{\text{pathway}}$):**
   $$S_{\text{pathway}}(P) = \sum_{v \in P} \mathbf{p}_{\infty}(v) \cdot w(v)$$
   Where $w(v)$ is the biological essentiality weight of node $v$ in pathway $P$.

---

## Engine 4: Pharmacokinetics (PBPK) & Exposure Prediction Engine

### 4.1 Objective & Scope
Estimates active constituent bioavailability, gut wall permeation, hepatic first-pass metabolism, and systemic plasma concentration ($C_{\text{max}}$, $T_{\text{max}}$, $\text{AUC}_{0-\infty}$).

### 4.2 Mathematical Formulation
1. **Two-Compartment Pharmacokinetic Differential Equations:**
   $$\frac{dC_{\text{gut}}}{dt} = -k_a \cdot C_{\text{gut}}$$
   $$\frac{dC_{\text{central}}}{dt} = \frac{k_a \cdot F \cdot \text{Dose}}{V_d} - \left( \frac{CL_{\text{renal}} + CL_{\text{hepatic}}}{V_d} + k_{12} \right) C_{\text{central}} + k_{21} C_{\text{peripheral}}$$
   $$\frac{dC_{\text{peripheral}}}{dt} = k_{12} C_{\text{central}} - k_{21} C_{\text{peripheral}}$$
2. **CYP3A4 / P-gp Inhibition Modulation by Piperine:**
   $$CL_{\text{hepatic, modulated}} = \frac{CL_{\text{hepatic, baseline}}}{1 + \frac{[I_{\text{piperine}}]}{K_{i,\text{CYP3A4}}}}$$

---

## Engine 5: Contextual Safety & Toxicology Gatekeeper

### 5.1 Objective & Scope
Executes multi-tiered safety verification encompassing Schedule E1 botanical restrictions, teratology, organ accumulation, and herb-drug interactions (HDI).

### 5.2 Mathematical Formulation & Rules
1. **Safety Verdict Logic:**
   $$\text{Verdict} = \begin{cases} 
   \text{BLOCK} & \text{if } \text{Schedule E1 Unpurified} \lor \text{Absolute Teratogenic Flag} \lor \text{Fatal HDI} \\
   \text{CAUTION} & \text{if } \text{Dose } > \text{TD}_{10} \lor \text{eGFR} < 30 \lor \text{Moderate HDI} \\
   \text{PASS} & \text{otherwise}
   \end{cases}$$
2. **Margin of Safety (MoS):**
   $$\text{MoS} = \frac{\text{NOAEL}_{\text{animal}} \times \text{HED\_Factor}}{\text{Estimated Clinical Daily Dose}}$$
   If $\text{MoS} < 100$, status is automatically set to `CAUTION`.

---

## Engine 6: Contradiction & Conflict Resolution Engine

### 6.1 Objective & Scope
Detects, preserves, and tracks opposing scientific claims between classical literature, modern toxicology, and contradictory clinical trials.

### 6.2 Mathematical Model & Invariant
1. **Directional Conflict Matrix ($C_{AB}$):**
   $$C_{AB} = \begin{cases} 
   1 & \text{if } \text{Direction}(A) = \text{AGONIST} \land \text{Direction}(B) = \text{ANTAGONIST} \\
   1 & \text{if } \text{Toxicity}(A) = \text{LETHAL} \land \text{Safety}(B) = \text{BENIGN} \\
   0 & \text{otherwise}
   \end{cases}$$
2. **Immutability Invariant:** Contradictions are **never overwritten or deleted**. When resolved by empirical experiment, resolution status transitions to `RESOLVED_WITH_EVIDENCE` while preserving historical conflict lineage.

---

## Engine 7: Multi-Component Synergy Engine

### 7.1 Objective & Scope
Quantifies non-linear pharmacodynamic and pharmacokinetic interactions among multi-herbal constituents.

### 7.2 Mathematical Models
1. **Bliss Independence Model ($I_{\text{Bliss}}$):**
   $$E_{\text{expected}}(A, B) = E_A + E_B - (E_A \cdot E_B)$$
   $$\Delta I_{\text{Bliss}} = E_{\text{observed}}(A, B) - E_{\text{expected}}(A, B)$$
   Where $\Delta I_{\text{Bliss}} > 0.10$ indicates synergy.
2. **Loewe Additivity Index ($CI_{\text{Loewe}}$):**
   $$CI = \frac{D_A}{IC_{50,A}} + \frac{D_B}{IC_{50,B}}$$
   Where $CI < 0.8$ indicates synergistic interaction.

---

## Engine 8: Unani ↔ Biomedical Semantic Translation Engine

### 8.1 Objective & Scope
Bridges classical humoral concepts (Mizaj, Akhlat, Afaal) to contemporary cellular-molecular phenotypes without reductionist distortion.

### 8.2 Six-Tier Semantic Mapping Pipeline
1. **Classical Concept:** Nominal descriptor in canon (e.g. *Balgham-e-Fasid*).
2. **Operational Definition:** Functional systemic disturbance (e.g. viscous inflammatory transudate accumulation).
3. **Observable Clinical Features:** Traditional physical diagnosis (Pulse, Tongue, Urine, Complexion).
4. **Clinical Phenotype:** Contemporary ICD-10 / NAMASTE cross-reference (e.g. *M10.0 Gout*).
5. **Biomarker Associations:** Surrogate laboratory measurements (e.g. Serum Uric Acid, hs-CRP).
6. **Calibrated Evidence Status:** `ESTABLISHED`, `SUPPORTED`, `HYPOTHESIS`, or `UNKNOWN`.

---

## Engine 9: Formulation Compiler (R&D Architecture Engine)

### 9.1 Objective & Scope
Optimizes multi-botanical composition ratios satisfying therapeutic objectives, safety bounds, and synergistic bioavailability.

### 9.2 Mathematical Optimization Formulation
$$\max_{\mathbf{x}} \quad \Phi(\mathbf{x}) = \sum_{i=1}^n x_i \cdot \alpha_i \cdot \text{Affinity}_i + \lambda \sum_{i < j} x_i x_j \cdot \Delta I_{\text{Bliss}}(i,j) - \gamma \sum_{i=1}^n x_i \cdot \text{Tox}_i$$
Subject to:
$$\sum_{i=1}^n x_i = 1.0, \quad x_i \ge 0$$
$$x_i \le \text{MaxDoseSafetyLimit}_i \quad \forall i \in \{1,\dots,n\}$$
$$\text{Schedule E1 Mudabbar Clearance} = \text{TRUE}$$

---

## Engine 10: Next-Best Experiment Recommendation Framework

### 10.1 Objective & Scope
Scores and prioritizes wet-lab bioassays and clinical protocols to achieve maximum scientific information gain per unit expenditure.

### 10.2 Mathematical Scoring Index
$$\text{Priority Score} = \frac{\Delta H(X) \cdot V_{\text{clinical}} \cdot U_{\text{epistemic}} \cdot \mathcal{F}_{\text{technical}}}{\log_{10}(\text{Cost}_{\text{USD}} \cdot \text{Turnaround}_{\text{days}})}$$
Where:
- $\Delta H(X)$: Shannon Information Gain from resolving hypothesis $X$.
- $V_{\text{clinical}}$: Therapeutic impact factor (0.0 to 1.0).
- $U_{\text{epistemic}}$: Baseline model uncertainty (0.0 to 1.0).
- $\mathcal{F}_{\text{technical}}$: Assay feasibility (0.0 to 1.0).

---

## 2. Definitive Engineering Conclusion

This Master Blueprint transitions ZAYVORA ZFIE from conceptual schemas into a **mathematically rigorous, reproducible, and verifiable pharmaceutical intelligence platform**. Every formula, boundary condition, and evidence ladder invariant is implemented in the repository and governed by automated verification suites.
